All In Biotech

Drug Trial Radar · NCT06479135

Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib

A Phase 3, Randomized, Double-blind, Add-on Study Evaluating the Safety and Efficacy of Navtemadlin Plus Ruxolitinib vs Placebo Plus Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib

Last checked: Nov 19, 2026Latest source record: Sep 25, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 600 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

600

Planned (sponsor's estimate)

Start

Jun 3, 2024

Primary completion

Dec 31, 2026

Study completion Dec 31, 2028

Sponsor

Lead sponsor
Kartos Therapeutics, Inc.Industry
Sponsor type
Industry
First posted
Jun 28, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This clinical trial is evaluating whether addition of navtemadlin to ruxolitinib treatment will provide more clinical benefit than ruxolitinib alone for patients with Myelofibrosis who have a suboptimal response to ruxolitinib treatment alone. Subjects will start by receiving ruxolitinib alone in the run-in period. Those who demostrate a suboptimal response from ruxolitinib alone will then be randomized 2:1 to receive navtemadlin or navtemadlin placebo as add-on treatment to their ongoing ruxolitinib. Randomized means that subjects will be assigned to a group by chance, like a flip of a coin. The study is blinded, meaning the subjects, doctors, central endpoint assessors and sponsor will not know which add on treatment (navtemadlin or navtemadlin placebo) the subject is receiving.

Conditions

  • Myelofibrosis
  • Post-PV MF
  • Post-ET Myelofibrosis
  • Primary Myelofibrosis
  • MF

Interventions

  • NavtemadlinDrug

    Navtemadlin is an investigational MDM2 inhibitor

  • Navtemadlin placeboDrug

    Navtemadlin placebo

  • RuxolitinibDrug

    Ruxolitinib is a janus kinase 1/2 inhibitor

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To compare spleen volume reduction (SVR35) between Arm 1 and Arm 2Time frame: 24 weeks
  2. To compare total symptom score reduction (TSS50) between Arm 1 and Arm 2Time frame: 24 weeks

Locations

215 sites in 19 countries. Site status is shown where the registry gives one.

  • UAB Hospital

    Birmingham, Alabama · Recruiting

  • Banner MD Anderson Cancer Center

    Gilbert, Arizona · Recruiting

  • Mayo Clinic - Phoenix

    Phoenix, Arizona · Recruiting

  • UC San Diego Moores Cancer Center

    La Jolla, California · Recruiting

  • UCLA Hematology/Oncology Clinic - Los Angeles

    Los Angeles, California · Recruiting

  • Scripps Health, Prebys Cancer Center

    San Diego, California · Recruiting

  • The Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center

    Torrance, California · Recruiting

  • Rocky Mountain Cancer Centers - Aurora

    Aurora, Colorado · Recruiting

  • Medical Oncology Hematology Consultants, PA

    Newark, Delaware · Recruiting

  • MedStar Georgetown University Hospital, Lombardi Comprehensive Cancer Center

    Washington D.C., District of Columbia · Recruiting

  • Mayo Clinic - Jacksonville

    Jacksonville, Florida · Recruiting

  • University of Miami

    Miami, Florida · Recruiting

  • AdventHealth Cancer Institute

    Orlando, Florida · Recruiting

  • Moffitt Cancer Center

    Tampa, Florida · Recruiting

  • Mission Cancer + Blood

    Des Moines, Iowa · Recruiting

  • University of Kansas Cancer Center - Westwood

    Westwood, Kansas · Recruiting

  • Norton Cancer Institute

    Louisville, Kentucky · Recruiting

  • Mary Bird Perkins Cancer Center

    Baton Rouge, Louisiana · Recruiting

  • Johns Hopkins Sidney Kimmel Comprehensive Cancer Center

    Baltimore, Maryland · Recruiting

  • The Center for Cancer and Blood Disorders

    Bethesda, Maryland · Recruiting

  • Dana Farber Cancer Institute

    Boston, Massachusetts · Recruiting

  • University of Michigan Hospital

    Ann Arbor, Michigan · Recruiting

  • Henry Ford Cancer Institute - Brigitte Harris Cancer Pavilion

    Detroit, Michigan · Recruiting

  • Nebraska Hematology - Oncology, P.C.

    Lincoln, Nebraska · Recruiting

  • Mohtaseb Cancer Center and Blood Disorders

    Henderson, Nevada · Recruiting

  • Hackensack University Medical Center

    Hackensack, New Jersey · Recruiting

  • Brookdale University Hospital and Medical Center

    Brooklyn, New York · Recruiting

  • Cayuga Cancer Center

    Ithaca, New York · Recruiting

  • Northwell Health, R.J. Zuckerberg Cancer Center

    Lake Success, New York · Recruiting

  • ICAHN School of Medicine at Mount Sinai

    New York, New York · Recruiting

  • Montefiore Einstein Comprehensive Cancer Center

    The Bronx, New York · Recruiting

  • Medical University of South Carolina (MUSC)

    Charleston, North Carolina · Recruiting

  • Atrium Health Levine Cancer Institute

    Charlotte, North Carolina · Recruiting

  • Duke University Medical Center

    Durham, North Carolina · Recruiting

  • Regional Medical Oncology Center

    Wilson, North Carolina · Recruiting

  • Atrium Health Wake Forest Baptist

    Winston-Salem, North Carolina · Recruiting

  • Gabrail Cancer Center

    Canton, Ohio · Recruiting

  • University of Cincinnati Medical Center

    Cincinnati, Ohio · Recruiting

  • Cleveland Clinic Cancer Center at Fairview Hospital

    Cleveland, Ohio · Recruiting

  • Cleveland Clinic

    Cleveland, Ohio · Recruiting

Showing 40 of 215 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.